Competitive Advantage of Our Technology

5Fluorouracil (5FU) is a therapeutic for the treatment of multiple cancers, including breast and colon cancers. In the United States, approximately 275,000 cancer patients receive 5FU annually. It is estimated that three percent (3%) of those patients develop some degree of toxic reaction. Patients suffering toxic reactions are difficult and expensive to treat further. Approximately, 15% of those developing toxic reaction, will die as a result of exposure to 5FU. Death is typically caused by cardiotoxicity. More than 1,300 patients in the United States die each year as a result of 5FU toxicity. These deaths are all potentially avoidable if patients that are likely to get adverse reaction with 5FU treatment are detected prior to treatment. Patent Estate

This technology consists of the following patents and patent applications:

I. United States Patent Number 5,856,454 entitled ``cDNA for Human and Pig Dihydropyrimidine Dehydrogenase,'' issued January 5, 1999 (HHS Ref. No. E1571994/0US01);

II. United States Patent Number 6,015,673 entitled ``Cloning and Expression of cDNA for Human Dihydropyrimidine Dehydrogenase,'' issued January 18, 2000 (HHS Ref. No. E1571994/0US03);

III. United States Patent Number 6,787,306 entitled ``Methods and Compositions for Detecting Dihydropyrimidine Dehydrogenase Splicing Mutations,'' issued September 7, 2004 (HHS Ref. No. E1571994/1US 01);

IV. United States PreGrant Publication number 2005/0136433A1 corresponding to application serial number 10/911237 entitled ``Methods and Compositions for Detecting Dihydropyrimidine Dehydrogenase Splicing Mutations,'' published June 23, 2005 (HHS Ref. No. E1571994/1US19) and all issued and pending counterparts in Europe, Canada, and Australia.

Next Step: Teleconference

There will be a teleconference where the principal investigator will explain this technology. Licensing and collaborative research opportunities will also be discussed. If you are interested in participating in this teleconference please call or email Mojdeh Bahar; (301) 4352950; baharm@mail.nih.gov. OTT will then email you the date, time and number for the teleconference.

Dated: June 26, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer. National Institutes of Health.
[FR Doc. E815182 Filed 7208; 8:45 am]
BILLING CODE 414001P

SUMMARY: Methods and Compositions Relating to Detecting Dihydropyrimidine Dehydrogenase; public teleconference,

DOCUMENT BODY: Technology Summary

This technology relates to a method of detecting DPD Splicing Mutations.

Technology Description

Scientists at the National Cancer Institute have discovered a method detecting DPD Splicing Mutations. This method can identify patients with such mutations, and thereby alert the health care provider that the patient will have an adverse reaction to the chemotherapeutic agent, 5Fluorouracil.

The invention relates to methods and compositions that are useful for detecting deficiencies in DPD levels in mammals including humans. Cancer patients having a DPD deficiency are at risk of a severe toxic reaction to the commonly used anticancer agent 5fluorouracil (5FU). The technology encompasses DPD genes from human and pig, methods for detecting the level of nucleic acids that encode DPD in a patient, and nucleic acids that are useful as probes for this purpose.

Novel applications of the methods include:

Competitive Advantage of Our Technology

5Fluorouracil (5FU) is a therapeutic for the treatment of multiple cancers, including breast and colon cancers. In the United States, approximately 275,000 cancer patients receive 5FU annually. It is estimated that three percent (3%) of those patients develop some degree of toxic reaction. Patients suffering toxic reactions are difficult and expensive to treat further. Approximately, 15% of those developing toxic reaction, will die as a result of exposure to 5FU. Death is typically caused by cardiotoxicity. More than 1,300 patients in the United States die each year as a result of 5FU toxicity. These deaths are all potentially avoidable if patients that are likely to get adverse reaction with 5FU treatment are detected prior to treatment. Patent Estate

This technology consists of the following patents and patent applications:

I. United States Patent Number 5,856,454 entitled ``cDNA for Human and Pig Dihydropyrimidine Dehydrogenase,'' issued January 5, 1999 (HHS Ref. No. E1571994/0US01);

II. United States Patent Number 6,015,673 entitled ``Cloning and Expression of cDNA for Human Dihydropyrimidine Dehydrogenase,'' issued January 18, 2000 (HHS Ref. No. E1571994/0US03);

III. United States Patent Number 6,787,306 entitled ``Methods and Compositions for Detecting Dihydropyrimidine Dehydrogenase Splicing Mutations,'' issued September 7, 2004 (HHS Ref. No. E1571994/1US 01);

IV. United States PreGrant Publication number 2005/0136433A1 corresponding to application serial number 10/911237 entitled ``Methods and Compositions for Detecting Dihydropyrimidine Dehydrogenase Splicing Mutations,'' published June 23, 2005 (HHS Ref. No. E1571994/1US19) and all issued and pending counterparts in Europe, Canada, and Australia.

Next Step: Teleconference

There will be a teleconference where the principal investigator will explain this technology. Licensing and collaborative research opportunities will also be discussed. If you are interested in participating in this teleconference please call or email Mojdeh Bahar; (301) 4352950; baharm@mail.nih.gov. OTT will then email you the date, time and number for the teleconference.

Dated: June 26, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer. National Institutes of Health.
[FR Doc. E815182 Filed 7208; 8:45 am]
BILLING CODE 414001P